Contents: News Stories, 2001 Nanoprobes receives Phase 1 SBIR grant on Enzyme Metallography for Biological Detection from NIGMS (October 9, 2001) Nanoprobes reagents now available from Molecular Probes (October 9, 2001) Browse the company news archive...   12/21/07: 1-Hr His-Tag Detection on Westerns 8/21/07: Review Paper: Enzmet for In Situ Hybridization 4/17/07: Announcing AuroVist: Xray Contrast for MicroCT 1/10/07: Phase 2 SBIR Grant for MicroCT Imaging   11/10/06: Gold X-Ray Contrast Agents 7/20/06: First 3D Distribution of 45S rDNA 3/15/06: Major Expansion Completed   9/5/03: New Product: Ni-NTA-Nanogold® 3/25/03: New Product: Alexa FluoroNanogold   9/9/02: NIH SBIR: MRI Contrast Agents 9/4/02: NIH STTR: Her-2/neu Assay 7/8/02: NIH SBIR: Molecular Beacons II   10/9/01: NIH SBIR: Enzyme Metallography 10/9/01: Reagents from Molecular Probes   9/5/00: NIH SBIR: Molecular Beacons 6/16/00: NIH STTR: Her-2/neu Amplification 4/19/00: Phase II of "Fast-Track" NIH SBIR grant 3/9/00: Larger Nanoprobes Facility 3/9/00: New NIH NCI SBIR Grant   11/15/99: New NIH NIDDK SBIR Grant 9/23/99: New NIH "Fast-Track" SBIR Grant 9/15/99: Gold Enhancement 9/15/99: Cy3-FluoroNanogold 1/29/99: NSF SBIR: Interconnect Fabrication   9/11/98: Phase I SBIR Grant 4/3/98: Phase II of "Fast-Track" SBIR Grant   9/8/97: "Fast-Track" SBIR Grant 9/5/97: New FluoroNanogold Papers 4/27/97: SBIR - Membrane Protein Labels.   10/7/96: SBIR - Ni-NTA-Gold probes 10/3/96: NIH Phase II SBIR 8/20/96: Ultrasensitive In Situ Hybridization 8/20/96: Gold Lipids 5/25/96: Nanogold-Peptide Probes 2/22/96: NSF Phase I SBIR to Nanoprobes   10/17/95: Phase II SBIR to Nanoprobes   10/94: 3, 5, 10, 15 and 30nm Colloidal Gold 9/94: FluoroNanogold 6/92: Nanogold® Gold Labeling Reagents   News Index

Nanoprobes Receives Phase 1 SBIR Grant on Enzyme Metallography for Biological Detection from NIGMS

The new detection system utilizes the selective deposition of metal from solution onto specific sites within cells and tissues labeled with an enzyme-linked antibody or other biomolecule conjugate targeted to the sites of interest. In preliminary blotting and staining experiments, it has been found to give high sensitivity combined with high spatial and detail resolution within samples, making it useful both for the identification and quantitation of cellular features for disease identification, and for microscopic and ultrastructural investigation. This technology will be developed for use as a general staining and detection method for the immunohistochemical staining of proteins, and also in situ hybridization detection of genetic changes in cells and tissue sections. The method is straightforward, and compared with current methods, has the potential advantages of greater speed and simplicity as well as improved sensitivity and resolution.

The chemistry of the new detection system will be developed and optimized at Nanoprobes, Incorporated by Dr. Richard D. Powell, Dr. James F. Hainfeld, Dr. Wenqiu Liu and Dr. Vishwas Joshi. Further optimization and testing in immunohistochemical staining and in situ hybridization experiments will be conducted by Dr. Raymond R. Tubbs, Dr. Linda Vargo, and James D. Pettay at the Cleveland Clinic Foundation (Cleveland, OH).

Nanoprobes, Inc., founded in November 1990, researches and develops the biomedical and high-technology applications of metal nanoparticles and autometallography. The company is a leader in immunogold technology, with products which include the 1.4 nm Nanogold® cluster immunoprobes and labeling reagents, the combined fluorescent and gold immunoprobe FluoroNanogold which is used for correlative fluorescence and electron microscopy, and sensitive DNA detection reagents.

For more information, contact:

Telephone: (919) 845-6324
Fax: (631) 980-3608
E-mail rpowell@nanoprobes.com.
WWW: www.nanoprobes.com

contents

Nanoprobes Reagents Now Available from Molecular Probes

Nanoprobes, Incorporated and Molecular Probes plan to offer additional products and new reagents under this agreement in the future, including our line of FluoroNanogold combined fluorescent and gold probes. New products currently pending commercial release include combined fluorescent and gold probes labeled with Molecular Probes ALEXA fluorescent dyes. These are expected to offer improved performance over the fluorescein and Nanogold conjugates, and will enable correlative fluorescent and electron microscopy labeling at different wavelengths.

Nanoprobes, Inc., founded in November 1990, researches and develops the biomedical and high-technology applications of metal nanoparticles and autometallography. The company is a leader in immunogold technology, with products which include the 1.4 nm Nanogold® cluster immunoprobes and labeling reagents, the combined fluorescent and gold immunoprobe FluoroNanogold which is used for correlative fluorescence and electron microscopy, and sensitive DNA detection reagents.

For more information, contact:

Telephone: (631) 205-9490
Fax: (631) 205-9493
E-mail nano@nanoprobes.com.
WWW: www.nanoprobes.com

contents